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Abstract 
Background: We have investigated the potential anticancer effects of karanjin, a principal furanoflavonol constituent 
of the Chinese medicine Fordia cauliflora, using cytotoxic assay, cell cycle arrest, and induction of apoptosis in three 
human cancer cell lines (A549, HepG2 and HL‑60 cells).
Results: MTT cytotoxic assay showed that karanjin could inhibit the proliferation and viability of all three cancer cells. 
The induction of cell cycle arrest was observed via a PI (propidium iodide)/RNase Staining Buffer detection kit and 
analyzed by flow cytometry: karanjin could dose‑dependently induce cell cycle arrest at G2/M phase in the three cell 
lines. Cell apoptosis was assessed by Annexin V‑FITC/PI staining: all three cancer cells treated with karanjin exhibited 
significantly increased apoptotic rates, especially in the percentage of late apoptosis cells.
Conclusion: Karanjin can induce cancer cell death through cell cycle arrest and enhance apoptosis. This compound 
may be effective clinically for cancer pharmacotherapy.
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Background
Fordia cauliflora Hemsl, belongs to the family of Legu-
minosae and is, known in Chinese as “Shuiluosan”. It 
has been used in China as a traditional folk medicine 
for bronchitis, rheumatism, bruise, dementia of chil-
dren, and valetudinarianism [1, 2]. Previous studies have 
shown that this plant could improve short and long-term 
memories of mice [3], with additional anti-hypertension 
[4], anti-inflammatory [5], and antioxidative effects [6].
Karanjin (structure depicted in Figure  1) is a major 
active furanoflavonol constituent of Fordia cauliflora 
Hemsl. It is associated with the above pharmacological 
activities, and has been reported to exert anti-hyper-
glycemic action [7] and ability of inducing GLUT4 
translocation in skeletal muscle cells by increasing AMP-
activated protein kinase activity [8]. In addition, Michae-
lis et  al. found that karanjin could interfere with drug 
efflux mediated by ATP-binding cassette (ABC) trans-
porters ABCB1, ABCC1, and ABCG2, and enhanced 
their ATPase activity. These mechanisms may be relevant 
to the anti-cancer effect of karanjin, especially in combi-
nation with other anti-cancer drugs that interfere with 
ABC transporters [9]. Flavonoids are widely distributed 
and used in traditional Chinese medicine for treating 
various diseases by virtue of their anticancer, antioxi-
dant, antibacterial and anti-inflammatory activities. For 
example, Maurya et al. reported that bisfuranoflavonoids, 
furanorotenoids and dihydrofurano compounds have 
shown efficacy against human cancer cells [10]. Therefore 
it is logical to speculate  that  karanjin may also possess 
anti-cancer activity. However, to date this hypothesis has 
not been supported by any experimental evidence. In this 
study, karanjin isolated from Fordia cauliflora Hemsl. 
was investigated for its anti-tumor effects using cell 
cycle arrest and induction of apoptosis in three cancer 
cell lines: human lung adenocarcinoma cell line (A549), 
human hepatocellular carcinoma cell line (HepG2), and 
human acute promyelocytic leukemia cell line (HL-60 
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based mainly on our experience in working on them as 
well as the high prevalence and mortality of these three 
cancers in humans.
Results and discussion
Effect of Karanjin on growth of tumor cells
Prompted by our interest in the antitumor activity of 
flavonoid compounds, we have investigated the cyto-
toxic effect and apoptotic property of karanjin in vari-
ous human cancer cell lines A549, HepG2, and HL-60 
representing respectively lung adenocarcinoma, hepato-
carcinoma and promeylocytic leukemia that are preva-
lent with high mortality in humans. The inhibitory effect 
of karanjin on these cancer cell lines was determined 
by the cytotoxic MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 
diphenyltetrazolium bromide) assay. Cells were exposed 
to karanjin at various concentrations (Dr Zhang, please 
consider if you like to list the concentrations here in 
brackets like how you list the incubation times) over dif-
ferent incubation periods (24, 48 and 72 h). As shown in 
Figure  2, proliferation of karanjin-treated A549, HepG2 
and HL-60 cells was significantly suppressed compared 
to untreated cells. The IC50 (half (50%) maximal inhibi-
tory concentration) values of karanjin on these three 
cell lines over different treatment time periods (Table 1) 
showed that karanjin inhibition of A549, HepG2, HL-60 
cells was time-dependent. IC50 values of karanjin-treated 
HepG2 cells were close to those of HL-60 cells over the 
same incubation times. However, IC50 values of A549 
cells decreased steeply with increased drug exposure 
time (about 2.3- and 3.0-folds from 24 to 48 and 24 to 
72 h), and they were higher than the corresponding IC50 
values of HepG2 and HL-60 cells. These observation 
and comparison suggest that the HepG2 and HL-60 cell 
lines may be more sensitive to Karanjin with respect to 
viability and proliferation. Furthermore, we use gemcit-
abine, 5-fluorouracil (5-FU) and Cytosine Arabinoside 
(Ara-C) as positive-control anti-cancer agents for these 
three cell lines, respectively. These cytotoxic drugs have 
shown selective efficacy on the three types of cancer cells. 
IC50 values of A549 cells for treatment with gemcitabine 
over 72  h was 0.04 ±  0.01  µM, that of 5-FU on HepG2 
cell line 49.9 ± 5.1 µM (72 h), and for Ara-C on HL-60 
cells 2.6 ± 0.8 µM. We found that the cytostatic effect of 
karanjin was higher than 5-FU, but lower than gemcti-
tabine and Ara-C. Even so, these results also could sug-
gest that karanjin exhibited a strong inhibitory effect on 
these human cancer cells.
Karanjin induced cell cycle arrest at G2/M phase in cancer 
cell lines
The cell cycle is a cyclic process of cell division. Accord-
ingly, induction of cell cycle arrest may be a strategy 
Figure 1 Chemical structure of karanjin.
Figure 2 The cytotoxic effects of human cancer cell lines. MTT assay 
was performed after treatment with karanjin for 24, 48 and 72 h. a 
A549 cells, b HepG2 cells, and c HL‑60 cells. All data are presented as 
mean ± SD values (n = 3).
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for cancer therapy. Based on results of the above MTT 
assays, karanjin exhibited a potent inhibitory effect on 
the proliferation of all three human cancer cells that were 
studied. In order to investigate the effect of karanjin on 
the cell cycle phase distribution in these three cancer 
cell lines, PI (propidium iodide)/RNase Staining Buffer 
detection kit was used in the flow cytometric analysis. As 
shown in Figure 3a, b and Table 2, the percentage of A549 
cells in G2/M phase increased dose-dependently upon 
72 h treatment with karanjin, while S-phase cells showed 
moderate yet statistically significant decreases, and A549 
cells in G0/G1 phase decreased. Figure 3c, d and Table 2 
show that treatment of HepG2 cells with karanjin at 2.5 
and 5.0 µM for 72 h resulted in decreased percentage of 
cells at G0/G1 phase, while cells of S and G2/M phases 
increased,. As shown in Figure 3e, f and Table 2, incuba-
tion with karanjin for 72 h could induce cell cycle arrest 
at G2/M phase in HL-60 cells dose-dependently from 
2.0 to 4.0 and 6.0  µM, respectively. Our above results 
are similar to those of the other types of flavonoid com-
pounds [11–13]. Karanjin could decrease the percentage 
of cells at G0/G1 and S phases and increase significantly 
the percentage of cells in the G2/M phase in A549 cells. 
It could inhibit cell growth by inducing the accumula-
tion of S and G2/M phase cells in HepG2 cells. Expo-
sure of HL-60 cells to karanjin caused cell cycle arrest at 
the G2/M phase, and a significantly decreased distribu-
tion of cells in the G0/G1 phase. Although these results 
indicate that karanjin could inhibit the grown of all three 
cancer cells through cell cycle arrest, HL-60 and A549 
cells exhibited similar patterns of induction of cell cycle 
arrest. In summary, the cell cycle was markedly blocked 
at G2/M phase in A549 cells, moderately perturbed in 
HL-60 cells, and least arrested in HepG2 cells.
Karanjin induced apoptosis in cancer cells
Cell apoptosis is a normal physiological process of 
orderly controlled cell death for maintaining stable inter-
nal environment of the whole organism. There is evi-
dence that apoptosis is related to cell cycle arrest [14]. 
Compounds that can induce cell cycle arrest and apop-
totic cell death are generally considered to be poten-
tial anticancer drugs [15, 16]. The Annexin V-FITC/PI 
Table 1 IC50 values of  karanjin in  three cancer cell lines 
over different treatment times




A549 35.3 ± 5.3 15.1 ± 4.5 11.9 ± 3.1
HepG2 7.2 ± 0.7 6.2 ± 1.5 5.5 ± 1.3
HL‑60 10.0 ± 1.4 8.1 ± 0.8 6.8 ± 0.9
Figure 3 Karanjin induced cell cycle arrest at G2/M phase in cancer 
cell lines. a Effect of karanjin in A549 cells as analyzed using flow 
cytometry. b The percentages of A549 cells at different phases. c 
Effect of karanjin in HepG2 cells. d The percentages of HepG2 cells 
at different phases. e Effect of karanjin in HL‑60 cells. f The percent‑
ages of HL‑60 cells at different phases. All results are expressed as 
mean ± SD values from three independent experiments. P value of 
less than 0.05 (*P < 0.05, **P < 0.01, compared with the control group)
are considered significant.
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apoptosis detection assay was used to confirm if karanjin 
inhibited cell proliferation through apoptosis. As shown 
in Figure  4a, b and Table  3, treatment of A549 cancer 
cells with different doses of karanjin for 72 h resulted in 
significant increases in the ratios of early and late apop-
tosis cells, while the percentage of viable cells reduced. 
Figure  4c and Table  3 show that treatment of HepG2 
cells with 5.0 µM karanjin for 72 h resulted in decrease 
of viable cells to 26.33 ± 0.90%, increase in early apopto-
sis cells to 23.23 ± 0.29%, and increase in late apoptosis 
to 48.43 ± 0.90% compared to untreated percentages (all 
P  <  0.01). Figure  4d and Table  3 also show HL-60 cells 
displayed similarly high percentage of apoptosis cells 
upon treatment with karanjin for 72 h. The distribution 
of A549 and HL-60 apoptotic cells upon karanjin treat-
ment belonged predominantly to those of late apopto-
sis. However, the accumulation of HepG2 apoptotic cells 
was not only in late apoptosis, but also in early apoptosis. 
In addition, we found that decreases in viable cells and 
increases in apoptotic cells were dependent on karan-
jin concentration. The percentages of late apoptosis in 
HepG2 and HL-60 cells are higher than that of A549 cells 
upon treatment with karanjin at high dose. Such differ-
ent effects may be due to the differences between IC50 
values. These experimental data provided evidence for 
karanjin induced apoptosis in A549, HepG2 and HL-60 
cells, implying a strong correlation between inhibition of 
cell-proliferation and apoptosis. Many reports [17–19] 
have suggested the pathways of flavonoids for inducing 
Table 2 Cell cycle phase distribution of  A549, HepG2 
and HL-60 cells with various doses of karanjin for 72 h
Results are expressed as mean ± SD values from three independent 
experiments.
P value of less than 0.05 (* P < 0.05, ** P < 0.01, compared with the control 
group) are considered statistically significant.
Cell line Group Cell cycle distribution (%)
G0/G1 S G2/M
A549 Control 50.3 ± 2.0 40.5 ± 3.3 9.2 ± 1.5
4.0 µM 51.6 ± 2.5 36.9 ± 3.0 11.2 ± 0.9
6.0 µM 39.0 ± 1.4** 29.2 ± 1.7** 31.8 ± 2.8**
8.0 µM 14.0 ± 1.5** 25.6 ± 2.6** 60.4 ± 1.2**
HepG2 Control 49.9 ± 2.1 34.3 ± 2.1 15.8 ± 0.1
1.25 µM 46.8 ± 1.8 34.7 ± 2.0 18.5 ± 2.6
2.5 µM 35.0 ± 2.2** 43.3 ± 1.8** 21.7 ± 1.0**
5.0 µM 32.3 ± 1.8** 42.8 ± 1** 25 ± 1.0**
HL‑60 Control 28.8 ± 3.6 63.1 ± 4.5 8.0 ± 0.8
2.0 µM 9.6 ± 0.8** 65.5 ± 2.6 24.9 ± 2.7**
4.0 µM 4.2 ± 0.5** 57.0 ± 0.9 38.8 ± 0.5**
6.0 µM 4.9 ± 0.4** 53.0 ± 1.7* 42.1 ± 1.4**
Figure 4 Karanjin induced apoptosis in cancer cell lines. a Annexin 
V‑FITC/PI staining of A549 cells exposed to karanjin as analyzed 
by flow cytometry. b Data analyses of A549 cells. c Data analyses 
of HepG2 cells. d Date analyses of HL‑60 cells. Q1 necrosis, Q2 late 
apoptosis, Q3 early apoptosis, Q4 viable cell. All results are expressed 
as mean ± SD values from three independent experiments. P value of 
less than 0.05 (*P < 0.05, **P < 0.01, compared with the control group)
are considered significant.
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apoptosis. The pathways for karanjin-induced apoptosis 
need to be further elucidated. Our study has shown that 
treatment of A549, HepG2 and HL-60 cells with karan-
jin caused inhibition of cell proliferation by increased cell 
apoptosis, suggesting that karanjin may be a potential 
drug for anti-cancer treatment.
Conclusion
In this study, the effects of flavonoid karanjin as a poten-
tial anticancer agent on the proliferation and apoptosis of 
human cancer cell lines including A549, HepG2 and HL-60 
cells were investigated. The viability of these three cell 
lines was found to decrease both time and concentration 
dependently upon treatment with karanjin. In addition, all 
cell lines were shown to undergo accumulation of G2/M-
phase late apoptosis cells dose-dependently upon treatment 
with karanjin for 72 h. These findings suggest that karanjin 
has significant anti-cancer activity on A549, HepG2 and 
HL-60 cells by inducing cell cycle arrest and apoptosis.
Methods
Chemicals and reagents
The Karanjin used in this study was a gift from Profes-
sor Buming Liu at the Guangxi Key Laboratory of Tra-
ditional Chinese Medicine Quality Standards, Guangxi, 
China. Karanjin was isolated from plant Fordia cauliflora 
by repeated open-column chromatography and prepara-
tive reverse-phase high pressure liquid chromatography. 
Its structure was determined by UV, MS, 1H- and 13C-
NMR, and by comparison with literature values [20, 21]. 
Ultra-pure water was obtained from the Milli-Q Gradi-
ent Water System (Millipore Corporation, MA, USA). 
Human lung adenocarcinoma cell line A549, human 
hepatocellular carcinoma cell line HepG2, and human 
acute promyelocytic leukemia cell line HL-60 were pur-
chased from American Type Culture Collection (ATCC), 
Rockville, MD, USA. For culturing cells, phosphate 
buffer saline (PBS), Dulbecco’s Modified Eagele Medium 
(DMEM), RPMI medium 1640, 0.25% Trypsin–EDTA 
solution, penicillin–streptomycin solution and fetal 
bovine serum (FBS) were purchased from GIBCO Invit-
rogen Corp, Carlsbad, CA, USA. 3-[(4,5)-dimethylthia-
zol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) was 
purchased from Sigma Aldrich Chemical Co., St Louis, 
MO, USA. Cell Cycle Analysis Kit and Annexin V-FITC/
PI Apoptosis Detection Kit were purchased from Signal-
way Antibody (SAB) Co., Ltd. College Park, MD, USA.
Cell culture
The human HepG2 cells was cultured in DMEM medium 
with 10% FBS, 100 units/mL penicillin, 100 μg/mL strepto-
mycin in a 37°C humidified incubator with 5% CO2 atmos-
phere, A549 cells and HL-60 cells were cultured in RPMI 
Medium 1640 supplemented with 10% FBS, 100 UI/mL 
penicillin and 100 μg/mL streptomycin in humidified air at 
37°C with 5% CO2, respectively. The exponentially growing 
cells were collected and re-suspended in fresh media and 
then exposed to different concentrations of karanjin.
MTT assay
The inhibition of cell growth by karanjin was investi-
gated via the MTT assay [22]. A549 cells, HepG2 cells 
and HL-60 cells were seeded in 96 wells plate (LabServ, 
Thermo Fisher Scientific, Bei Jing, China) at 3  ×  103 
Table 3 Effects of incubation with karanjin for 72 h on cell apoptosis in A549, HepG2 and HL-60 cells
Results are expressed as mean ± SD values from three independent experiments.
P-value of less than 0.05 (* P < 0.05, ** P < 0.01, compared with the control group) are considered statistically significant.
Cell line Group Apoptosis distribution (%) in cells
Viable cell Early apoptosis Late apoptosis Necrosis
A549 control 91.97 ± 0.34 1.59 ± 0.41 6.08 ± 0.36 0.35 ± 0.11
4.0 µM 76.13 ± 5.99* 6.75 ± 1.04** 16.80 ± 5.08* 0.33 ± 0.02
6.0 µM 61.03 ± 0.99** 9.03 ± 1.27** 29.47 ± 1.08** 0.44 ± 0.12
8.0 µM 47.03 ± 1.43** 9.15 ± 0.92** 35.33 ± 1.72** 8.50 ± 0.92
HepG2 control 89.53 ± 1.37 1.16 ± 0.08 8.54 ± 0.83 0.79 ± 0.52
1.25 µM 88.10 ± 1.21 1.68 ± 0.15** 9.29 ± 1.56 0.93 ± 0.29
2.5 µM 80.83 ± 2.03** 2.70 ± 0.26** 15.40 ± 2.32** 1.07 ± 0.35
5.0 µM 26.33 ± 0.90** 23.23 ± 0.29** 48.43 ± 0.90** 2.02 ± 0.21
HL‑60 control 93.37 ± 0.33 1.10 ± 0.06 5.31 ± 0.22 0.23 ± 0.04
2.0 µM 82.77 ± 0.99** 1.72 ± 0.21** 14.97 ± 0.70** 0.58 ± 0.07
4.0 µM 56.33 ± 1.11** 2.38 ± 0.36** 39.40 ± 1.13** 1.93 ± 0.37
6.0 µM 43.00 ± 1.02** 2.24 ± 0.59* 53.53 ± 1.13** 1.25 ± 0.11
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cells/well. After incubation, they were treated with the 
karanjin at different concentrations for 24, 48 and 72 h. 
MTT solution (final concentration of 0.5  mg/mL in 
medium) was added to each well and incubated further 
for 4 h. The medium was removed and 100 μL of DMSO 
was added to each well to dissolve the purple crystals 
of formazan. Absorbance was measured at 570  nm 
with a microplate UV/VIS spectrophotometer (Infinite 
M200 PRO, Tecan Auatria GmbH 5082, Grödig, Auat-
ria); reference wavelength was 650 nm. The cell number 
was determined using a hemocytometer. IC50 values of 
karanjin were calculated by GraphPad Prism software. 
Cell viability (%) = ODtreated/ODcontrol (untreated) × 100.
Cell cycle analysis
The cell cycle analysis was determined as previously 
described [23]. Cells were seeded at about 2 × 104 cells/
well in six wells culture plates (LabServ, Thermo Fisher 
Scientific, Bei Jing, China) and duplicated wells were 
treated with karanjin at different concentrations for 72 h. 
Cells were then harvested and fixed in 70% (v/v) cold 
ethanol at 4°C overnight. After washing with ice-cold 
PBS, the fixed-cell pellets were collected by centrifuga-
tion and re-suspended in PI/RNase Staining Buffer (Cell 
Cycle Detection Kit, Signalway Antibody (SAB) Co. 
Ltd.) for staining of DNA and finally analysed on a flow 
cytometer (FACSAriaTM III; Beckon Dickinson and Co., 
B.D Biosciences, San Jose, CA, USA).
Cell apoptosis analysis
Apoptosis was quantified by the Annexin V-FITC assay 
[24]. Cells treated with different concentrations of karan-
jin for 72  h were harvested by trypsinization, washed 
twice with 4°C PBS, and re-suspended in binding buffer. 
Annexin V-FITC and Propidium iodide (PI) solution 
were then added to stain the cells before analysis by flow 
cytometry (Beckon Dickinson FACSAriaTM III flow 
cytometer).
Statistical analysis
Data analyses were performed using the IBM SPSS Sta-
tistics (International Business Machines Corp. Armonk, 
New York, USA) and GraphPad Prism softwares (Graph-
Pad Software, Inc., La Jolla, CA, USA). All results are 
expressed as mean ± SD values from three independent 
replicate experiments. P value of less than 0.05 (*P < 0.05, 
**P  <  0.01, compared with the control group)are con-
sidered to be statistically significant by using one-way 
ANOVA followed by the Student’s t test.
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